The Traderszone Network

Published in TZ Latest News 24 September, 2017 by The TZ Newswire Staff

AbbVie’s Unfazed by the Risk of Generic Humira

Over 60% of AbbVie Inc.’s (NYSE: ABBV) sales come from demand for Humira — an autoimmune-disease drug prescribed to patients with a variety of conditions — that racks up sales of $16 billion per year. Humira is also world’s top selling medicine.

AbbVie’s heavy reliance on Humira has investors nervous about what happens when Humira loses its patent protection, but perhaps, those worries are overblown based on what AbbVie’s management is telling investors.

read more